Vector

Abstract

A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use of the vector is capable of delivering the NOI and/or the POI to the tumor.

1 . A vector comprising a polynucleotide sequence encoding an antibody which binds 5T4 antigen on a mammalian cell, wherein said polynucleotide sequence is operably linked to an expression regulatory element functional in a mammalian cell.  
     
     
         2 . The vector of  claim 1 , wherein the mammalian cell is a tumor cell.  
     
     
         3 . The vector of  claim 2 , wherein said expression regulatory element is a tumor specific promoter enhancer.  
     
     
         4 . The vector of  claim 1 , wherein said polynucleotide sequence additionally comprises one or more effector domains selected from the group consisting of an enzyme, a pro-drug activating enzyme, a toxin, all or part of a cytokine, an effector domain of an immunoglobulin heavy chain, a domain which activates macrophage FcgR I, II, or III receptors, and a domain which confers protein stability.  
     
     
         5 . The vector of  claim 3 , wherein said polynucleotide encodes a fusion protein.  
     
     
         6 . The vector of  claim 4 , wherein said fusion protein is secreted.  
     
     
         7 . A method for expressing a polynucleotide sequence in a mammalian cell in culture, comprising delivering to said mammalian cell a vector comprising a polynucleotide sequence encoding an antibody which binds 5T4 antigen on a mammalian cell in operable linkage with an expression regulatory element functional in a mammalian cell, wherein said polynucleotide sequence is expressed in said mammalian cell.  
     
     
         8 . The method according to  claim 7 , wherein said polynucleotide sequence is expressed in and recovered from said mammalian cell.  
     
     
         9 . The method according to  claim 7 , wherein said polynucleotide sequence additionally comprises one or more effector domains selected from the group consisting of an enzyme, a pro-drug activating enzyme, a toxin, all or part of a cytokine, an effector domain of an immunoglobulin heavy chain, a domain which activates macrophage FcgR I, II, or III receptors, and a domain which confers protein stability.  
     
     
         10 . The method according to  claim 7 , wherein said polynucleotide encodes a fusion protein.  
     
     
         11 . The method according to  claim 7 , wherein said fusion protein is secreted.